Filing Details
- Accession Number:
- 0001140361-15-034919
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-09-11 19:53:22
- Reporting Period:
- 2015-09-10
- Filing Date:
- 2015-09-11
- Accepted Time:
- 2015-09-11 19:53:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1437402 | Ardelyx Inc. | ARDX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1611193 | W Jeffrey Jacobs | C/O Ardelyx, Inc. 34175 Ardenwood Blvd, Suite 200 Fremont CA 94555 | Svp, Technical Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-09-10 | 2,000 | $0.54 | 49,420 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-09-10 | 2,000 | $20.59 | 47,420 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2015-09-10 | 2,000 | $0.00 | 2,000 | $0.54 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
52,874 | 2021-08-11 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 25, 2015.
- Includes 754 shares acquired under the Issuer's Employee Stock Purchase Plan on August 31, 2015.
- This transaction was executed in multiple trades in prices ranging from $19.83 to $20.75, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The option is fully vested and exercisable.